A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma

The purpose of this study is to find the highest dose of an investigational drug called IMGN529 that can be given safely in patients with B-cell non-Hodgkin lymphoma (NHL) that has returned or continued to grow despite standard therapy.

IMGN529 is composed of two parts: an antibody that binds to a protein on lymphoma cells called CD37, and a chemotherapy drug called DM1 which is transported by the antibody and causes cancer cells to die. IMGN529 is given intravenously (by vein).